elearning

Register for free and gain unlimited access to our extensive elearning library
Earn CME points and track your learning activity with hundreds of hours of continuing medical education.
Bookmark and Share

Fundamentals of MRONJ (Medication-Related Osteonecrosis of the Jaw)

This short module is an up-to-date resource taking elements of the accredited learning developed in 2017, which incorporated the increasing advances in our knowledge, risk factors, prevention and best management of MRONJ.

The objective of this e-learning module is to raise the standards of identification and treatment of MRONJ in Europe through the development and distribution of e-learning.

Published in September 2020.

Fundamentals of MRONJ  (Medication-Related Osteonecrosis of the Jaw)
Module
English
0 CME Points

Target audience

All healthcare professionals including dental practitioners and nurse practitioners.

Learning objectives

By the end of this module you should be able to:

  • Describe measures to prevent ONJ in cancer patients
  • Describe the main risk factors for ONJ development
  • Learn when to suspect and how to arrive at an early diagnosis of ONJ
  • Describe what is the most appropriate management of ONJ in each patient
  • Learn how to effectively collaborate with the dentist, oncology nurse and other health care professionals, who manage cancer patients.

IT Requirements

This module requires the learner to have a good, stable internet connection and can run on Internet Explorer 7 and above, Mozilla Firefox, Google Chrome and Opera on either Windows or MacOS. Flash Add-on is also required to run this module.

If you are viewing this module on an iPad (through a browser), please download the free Articulate Mobile Player beforehand. Other tablet devices may not be compatible - please check for Flash compatibility.

If you are experiencing technical difficulties, please contact education@ecancer.org and we will get back to you as soon as possible.

Support

This module is made possible through an unrestricted grant from Amgen.